Lipoprotein(a)LILAC-UNINCT07177612
Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).
An observational study of Lipoprotein(a) and Lipoprotein(a), Hyper-Lp(a)-Emia, run by Changi General Hospital at 3 sites in 3 countries.
Trial summary
The goal of this observational study is to assess the if short educational videos about #LILAC-for-Lpa are feasible and accepted in improving the confidence, testing, and management on Lipoprotein(a). Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Lipoprotein(a), Lipoprotein(a), Hyper-Lp(a)-Emia
- How many people
- 20,000 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 9 Sep 2025to Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Child, Adult, Older adult
Study population: Study populations include healthcare professionals, patients, and members of the public.
Who may be able to join
- Participants include students, participants from institute of higher learning aged 16 and above.
- Participants aged 16 and above regardless of local or overseas, may also be from educational talks that Dr Loh is invited to speak at.
- Patients and members of the public aged 16 and above if they attend lipid awareness educational events.
- Participants aged 16 and above in patient support groups or patient advocacy networks.
Who cannot join
- Participants aged below 16 years old.
Trial locations and contacts
3 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
3 sites in 3 countries
About this study
The goal of this observational study is to assess the if short educational videos about #LILAC-for-Lpa are feasible and accepted in improving the confidence, testing, and management on Lipoprotein(a).
Read the detailed description
The aims of this study are to (1) assess the feasibility of using these educational videos about LILAC-for-Lp(a) to help improve confidence, testing and the management of Lp(a), (2) assess the acceptability in using short education videos about LILAC-for-Lp(a) and (3) to understand the knowledge gaps of Lp(a) in medical professionals through the additional questionnaire provided.
- Conditions
- Lipoprotein(a), Lipoprotein(a), Hyper-Lp(a)-Emia
- Keywords
- LILAC-for-Lpa, Educational Videos, lipoprotein(a), Lp(a)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthcare Professionals | This group includes participants who are doctors, nurses, pharmacists, allied health and healthcare related students | |
| Patients/Family/Public | This group includes participants who have high Lipoprotein(a) levels, or their family members, or members of the public. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement of Knowledge and awareness of Lp(a)
Survey and questionnaire on participants to assess knowledge and awareness
Measured: From enrolment to 3 months after
Secondary outcomes (2)
Acceptance of Educational Videos
Survey to determine if the educational videos are useful for them
Measured: From point of enrolment to 3 months
Lipoprotein(a) Testing
Survey to doctors on whether they are testing for Lipoprotein(a) in their patients prior to watching the educational videos, 3 months after, and 1 year after.
Measured: During enrolment to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start9 Sep 2025
- Primary completionAug 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Lipoprotein(a)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Changi General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Loh Wann Jia, Changi General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177612
- Sponsor's protocol ID
- CIRB2025-0274
- Acronym
- LILAC-UNI
- Status last verified
- Sep 2025
- First submitted
- 10 Sep 2025
- Last updated
- 22 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is an educational research survey
Publications
Loh WJ, Pang J, Simon O, Chan DC, Watts GF. Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore. Front Cardiovasc Med. 2025 Feb 14;12:1527351. doi: 10.3389/fcvm.2025.1527351. eCollection 2025.
PubMed 40027516Loh WJ, Watts GF, Lum E. A short educational video for improving awareness and confidence of healthcare professionals in managing lipoprotein(a): a pilot study based on LILAC-for-Lp(a). Eur J Cardiovasc Nurs. 2025 Jul 21;24(5):796-799. doi: 10.1093/eurjcn/zvaf052. No abstract available.
PubMed 40156158
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).
- ClinicalTrials.gov ID
- NCT07177612
- Acronym / sponsor ID
- LILAC-UNI / CIRB2025-0274
- Conditions
- Lipoprotein(a), Lipoprotein(a), Hyper-Lp(a)-Emia
- Keywords
- LILAC-for-Lpa, Educational Videos, lipoprotein(a), Lp(a)
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- Changi General HospitalUniversity, hospital or other
- Study start
- 9 Sep 2025 (actual)
- Primary completion
- Aug 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to assess the if short educational videos about #LILAC-for-Lpa are feasible and accepted in improving the confidence, testing, and management on Lipoprotein(a).
Detailed description
The aims of this study are to (1) assess the feasibility of using these educational videos about LILAC-for-Lp(a) to help improve confidence, testing and the management of Lp(a), (2) assess the acceptability in using short education videos about LILAC-for-Lp(a) and (3) to understand the knowledge gaps of Lp(a) in medical professionals through the additional questionnaire provided.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthcare Professionals | – | –This group includes participants who are doctors, nurses, pharmacists, allied health and healthcare related students |
| Patients/Family/Public | – | –This group includes participants who have high Lipoprotein(a) levels, or their family members, or members of the public. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Study populations include healthcare professionals, patients, and members of the public.
Key inclusion criteria (4 listed)
- Participants include students, participants from institute of higher learning aged 16 and above.
- Participants aged 16 and above regardless of local or overseas, may also be from educational talks that Dr Loh is invited to speak at.
- Patients and members of the public aged 16 and above if they attend lipid awareness educational events.
- Participants aged 16 and above in patient support groups or patient advocacy networks.
Key exclusion criteria (1 listed)
- Participants aged below 16 years old.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Improvement of Knowledge and awareness of Lp(a)
Time frame: From enrolment to 3 months after
Survey and questionnaire on participants to assess knowledge and awareness
2 secondary outcomes
Acceptance of Educational Videos
Time frame: From point of enrolment to 3 months
Lipoprotein(a) Testing
Time frame: During enrolment to 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2025.
- Background: PubMed 40027516Loh WJ, Pang J, Simon O, Chan DC, Watts GF. Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore. Front Cardiovasc Med. 2025 Feb 14;12:1527351. doi: 10.3389/fcvm.2025.1527351. eCollection 2025.
- Background: PubMed 40156158Loh WJ, Watts GF, Lum E. A short educational video for improving awareness and confidence of healthcare professionals in managing lipoprotein(a): a pilot study based on LILAC-for-Lp(a). Eur J Cardiovasc Nurs. 2025 Jul 21;24(5):796-799. doi: 10.1093/eurjcn/zvaf052. No abstract available.
- Individual participant dataSharing planned: No. This is an educational research survey
Related trials for Lipoprotein(a)
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Lipoprotein(a)
Recruiting
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
ASCVD, LDL-C
Active, not recruitingPhase 2
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
Lipoprotein Disorder
Active, not recruitingPhase 2
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Hypercholesterolemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lipoprotein(a) and Lipoprotein(a), Hyper-Lp(a)-Emia, run by Changi General Hospital at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Australia, Malaysia, Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement of Knowledge and awareness of Lp(a) (time frame: From enrolment to 3 months after). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07177612, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.